PT - JOURNAL ARTICLE AU - Hernandez, Carme AU - Herranz, Carme AU - Baltaxe, Erik AU - Seijas, Nuria AU - González-Colom, Rubèn AU - Asenjo, Maria AU - Coloma, Emmanuel AU - Fernandez, Joaquim AU - Vela, Emili AU - Carot-Sans, Gerard AU - Cano, Isaac AU - Roca, Josep AU - Nicolas, David AU - , TI - The Value of Admission Avoidance: Cost-Consequence Analysis of One-Year Activity in a Consolidated Service AID - 10.1101/2023.01.05.23284217 DP - 2023 Jan 01 TA - medRxiv PG - 2023.01.05.23284217 4099 - http://medrxiv.org/content/early/2023/01/07/2023.01.05.23284217.short 4100 - http://medrxiv.org/content/early/2023/01/07/2023.01.05.23284217.full AB - Background Many advantages of hospital at home (HaH), as a modality of acute care, have been highlighted, but controversies exist regarding the cost-benefit trade-offs.Objective To assess health outcomes and analytical costs of hospital avoidance (HaH-HA) in a consolidated service with over ten years of delivery of HaH in Barcelona (Spain).Methods A retrospective cost-consequence analysis of all first episodes of HaH-HA, directly admitted from the emergency room (ER) in 2017–2018, was carried out. HaH-HA was compared with a propensity-score-matched group of contemporary patients admitted to conventional hospitalization (Controls). Mortality, re-admissions, ER visits, and direct healthcare costs were evaluated.Registration ClinicalTrials.gov (26/04/2017; NCT03130283).Results HaH-HA and Controls (n=441 each) were comparable in terms of age (73 [SD16] vs 74 [16]), gender (male, 57% vs 59%), multimorbidity, healthcare expenditure during the previous year, case mix index of the acute episode, and main diagnosis at discharge. HaH-HA presented lower mortality during the episode (0 vs. 19 (4.3%); p < 0.001). At 30 days post-discharge, HaH-HA and Controls showed similar re-admission rates; however, ER visits were lower in HaH-HA than in Controls (28 (6.3%) vs 34 (8.1%); p = 0.044). Average costs per patient during the episode were lower in the HaH-HA group (€ 1,078) than in Controls (€ 2,171). Likewise, healthcare costs within the 30 days post-discharge were also lower in HaH-Ha than in Controls (p < 0.001).Conclusions The study showed higher performance and cost reductions of HaH-HA in a real-world setting. The identification of sources of savings facilitates scaling of hospital avoidance.Funding This article was funded by JADECARE project- HP-JA-2019 - Grant Agreement nº 951442 (2020-2023), a European Union’s Health Program 2014-2020.KEY POINTSHospital at home, modality hospital avoidance, shows high potential for value generation in real-world settings by improving health outcomes and generating cost-savings.Positive outcomes of hospital avoidance seem associated to adequate management change and digital support.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis article was funded by JADECARE project- HP-JA-2019 - Grant Agreement number 951442 a European Union Health Program 2014-2020.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Ethical Committee for Human Research at Hospital Clinic de Barcelona approved the study protocol (refs. 2017-0451 and 2017-0452), which waived the collection of informed consent for the secondary use of routine care data.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated and/or analyzed during the current study are not publicly available due to administrative reasons but are available from the corresponding author upon reasonable request.